Former UK Prime Minister David Cameron has publicly disclosed that he was recently treated for prostate cancer. His announcement has reignited national discussions on the urgent need for improved prostate cancer screening, particularly among high-risk groups. At 59, Lord Cameron said he felt compelled to share his experience to help drive awareness and encourage men to take proactive steps in monitoring their health.
A Diagnosis Prompted by Awareness
Lord Cameron explained in an interview with The Times that he sought medical evaluation earlier this year after his wife, Samantha Cameron, urged him to do so. The couple had listened to a BBC interview with entrepreneur Nick Jones, who spoke publicly about his own prostate cancer diagnosis and encouraged men to get tested.
Following an elevated prostate-specific antigen (PSA) test, Cameron underwent an MRI scan and a biopsy, which confirmed the presence of cancer. He subsequently received focal therapy, a targeted treatment that destroys cancer cells in the affected area using modalities such as focused ultrasound or electrical pulses. Cameron described the emotional impact of hearing the diagnosis, noting that even as tests were being done, he hoped each result “was probably nothing,” until the biopsy confirmed otherwise.
Prostate Cancer as a Major UK Health Challenge
Prostate cancer remains the most commonly diagnosed cancer among men in the United Kingdom, with roughly 55,000 new cases identified each year. One in eight men will develop prostate cancer during their lifetime, and the risk is even higher for Black men and for those with a family history of the disease. Despite its prevalence, prostate cancer is still the only major cancer in the UK without an established national screening programme.
Limitations of PSA Testing
PWhile widely used as an initial test, the PSA blood test has well-recognised limitations. A raised PSA level does not necessarily indicate cancer, as it can also rise due to infections, inflammation, or benign enlargement of the prostate. On the other hand, some men with significant prostate cancer may present with only mildly elevated or even normal PSA levels. These limitations have contributed to longstanding concerns about false positives, unnecessary biopsies, and the overtreatment of cancers that may not have required intervention. For these reasons, men over 50 in the UK can request a PSA test, but there is no population-wide screening recommendation.
A Crucial Juncture for Screening Policy
Lord Cameron’s intervention comes at a pivotal moment. The UK National Screening Committee (NSC) is expected to announce soon whether current evidence supports introducing a national screening programme or an initial rollout targeting high-risk populations. Nick Jones, whose advocacy influenced Cameron to seek testing, described this as a crucial period for prostate cancer prevention. He has urged the NSC to consider prioritising Black men and those with a family history as the first groups to be included in any new screening strategy.
Transform Trial: A Landmark Study
Momentum for screening reform has also been strengthened by a major national research programme. The £42 million Transform trial, jointly funded by Prostate Cancer UK and the National Institute for Health and Care Research, recently launched across the country. This study aims to identify the most effective approach for detecting prostate cancer by comparing innovative diagnostic pathways with current NHS practices, which typically rely on PSA testing and biopsies. Investigators hope that results from this trial could influence policy within the next two years and potentially shift evidence in favour of targeted screening.
Reaction from the Cancer Community
Leaders across the prostate cancer community have welcomed Cameron’s openness. Chiara De Biase, Director of Health Services at Prostate Cancer UK, described his decision to share his diagnosis as an important contribution to raising awareness. She noted that the UK loses 12,000 men each year to prostate cancer, many from a disease that is highly curable when detected early. She emphasised that the country has reached a tipping point, and that the absence of a screening programme is prolonging preventable outcomes.
Public awareness has also been influenced by high-profile individuals living with the disease. Last year, Olympic champion Sir Chris Hoy disclosed his diagnosis of advanced prostate cancer at age 49. His experience, discovered incidentally after imaging for unrelated shoulder pain, has reinforced the need for earlier and more proactive testing among younger men.
A Call to Action
Reflecting on his diagnosis, Lord Cameron acknowledged that discussing personal health matters does not come naturally to many men, himself included. However, he stated that he felt an obligation to speak publicly to encourage others to seek timely evaluation. Early detection, he emphasised, enabled him to identify the problem and treat it effectively. He added that he wished to join the growing number of voices calling for a targeted screening programme that would help diagnose prostate cancer at earlier, more treatable stages.
More about Celebrities and Cancer
Written by Nare Hovhannisyan, MD